LIXTE Biotechnology Holdings is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The summit brings together leaders in health, culture, science, and community to advance health equity for Black men and families, inspired by the music and legacy of De La Soul. The program was developed following the passing of founding member David Jolicoeur and is rooted in the group's song "Good Health," reflecting their evolution from musical pioneers to wellness advocates.
The event will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness. Developed in collaboration with Blacksmith holdings, the summit creates a space to connect scientific innovation with communities most impacted by health disparities. LIXTE stated that the summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA.
LIXTE Biotechnology Holdings is focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company has demonstrated that its lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LB-100 represents a pioneering effort in an entirely new field of cancer biology called activation lethality, advancing a new treatment paradigm covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company's sponsorship of the health equity summit represents a broader commitment to addressing health disparities while advancing scientific innovation in cancer treatment.
The full press release can be viewed at https://ibn.fm/0kkqK, and complete terms of use and disclaimers are available at http://IBN.fm/Disclaimer. The summit's focus on connecting scientific advancement with community health initiatives highlights growing recognition within the pharmaceutical industry that addressing health disparities requires both medical innovation and community engagement.
